Children’s Hospital and Aston University to get new child-friendly brain imaging facility
Birmingham Children’s Hospital and Aston University Institute of Health of Neurodevelopment (IHN) are to get a new, child-friendly magnetoencephalography (MEG) brain scanner.
A nine-strong clinical and research team led by Aston University’s, Dr Caroline Witton, was awarded an £800,000 grant from the Medical Research Council (MRC) Capital Funding for World Class Labs scheme. This has been supplemented by Aston University, giving a total budget of £2.5million to purchase the MEG scanner from French company MAG4Health and construct a new, magnetically shielded laboratory in the IHN building on campus, a short walk from our Children's Hospital, to house it.
The facility will be staffed and used by a joint team from IHN and our Neurophysiology Department, as part of a long-running partnership. It is expected to open in 2025. IHN is already registered with the Care Quality Commission (CQC) as a day hospital for children, making it an ideal host.
MEG is a brain imaging technology that measures tiny magnetic fields in the brain, which are caused by electrical activity. This allows researchers to map brain activity, useful for investigating brain function and for clinical applications.
Aston University has pioneered MEG technology for more than 30 years and together with Birmingham Children’s Hospital, has implemented the clinical use of MEG for planning brain surgery for children with epilepsy and brain tumours.
Conventional MEG scanners are fixed machines, into which the patient is asked to place their head and remain very still. This can be unpleasant or difficult for children. The optically pumped magnetometer (OPM) MEG machine is different.
The scanner uses an adjustable cap containing new sensors developed by the company, which is placed on the patient’s head. This is more convenient and comfortable especially for children, as it allows some degree of movement.
The OPM MEG can pinpoint and track the brain’s neuronal activity in real time to a precision that is not possible with other imaging technologies like magnetic resonance imaging (MRI). OPM MEG technology has huge potential to improve the understanding and care of neuronal disorders.
Research for the European Brain Council estimates that brain disorders cost €798billion annually in Europe alone.
IHN and Birmingham Children’s Hospital have a research programme in place for the OPM MEG, which is focussed on improving outcomes for children with a wide range of brain disorders including traumatic brain injury.
This will build on their existing work using MEG to help neurosurgeons plan brain surgery for children with epilepsy and brain tumours and understand what factors can determine better outcomes in these conditions. This can in future help rehabilitation specialists to carefully target their treatments.
Currently, MEG scanners are operated by specially trained technicians. However, the teams at Aston University and Birmingham Children’s Hospital will work with MAG4Health to develop the clinical practices and software that will allow data analysis to take place in hospitals, rather than it being limited to universities. This will mean that in future many more patients will be able to benefit from MEG.
Peter Bill, Lead Healthcare Scientist from our Children’s Hospital said: “This represents a fantastic opportunity to grow and develop our clinical workforce and to deliver a unique service for our patients and their families.
“This is building on a foundation of advancing practice in the healthcare sciences that has seen Aston University and our profession develop a successful MSc programme over a decade ago. I see this as an exciting example of how multidisciplinary and multiprofessional collaboration can improve patient care through innovation.”
Dr Witton said: “I am incredibly excited about the opportunities we have been given with this funding. OPM-MEG is the next frontier in our field, and I genuinely think that, because of our unique partnership with BCH, we have the chance to make a real difference to how MEG is used clinically.”